Lanreotide (Somatuline Depot): Complete Research Profile — Long-Acting Somatostatin Analog for Acromegaly and Neuroendocrine Tumor Research (2026)

# Lanreotide (Somatuline Depot): Complete Research Profile — Long-Acting Somatostatin Analog for Acromegaly and Neuroendocrine Tumor Research (2026)

> Research Use Only (RUO). Lanreotide (Somatuline Depot/Autogel) is discussed here strictly as a laboratory research reagent and FDA-approved pharmacological tool for in vitro, preclinical, and translational research. This profile is educational content for scientists and researchers. Nothing below constitutes medical advice, dosing guidance, or a recommendation for human or animal therapeutic use outside regulated clinical or research settings.

Lanreotide is a synthetic cyclic octapeptide somatostatin analog and the active ingredient in Somatuline Depot (USA) / Somatuline Autogel (EU). Originally approved by the FDA in 2007 for acromegaly and in 2014 for unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), lanreotide represents the long-acting, monthly-dosing formulation archetype of the somatostatin receptor ligand (SRL) pharmacological class.

For the foundational receptor biology, see the Peptides.SO somatostatin receptor biology guide. For analog siblings, see the octreotide research profile and the pasireotide (SOM230) profile.

---

Background: Somatostatin and Long-Acting Analogs

Native somatostatin (SST-14/SST-28) is an endogenous regulatory peptide that signals through five class A GPCRs — SSTR1–SSTR5 — mediating broad inhibitory (anti-secretory, anti-proliferative) signaling across the CNS, pituitary, pancreas, GI tract, and neuroendocrine tumors. Its clinical utility is limited by a half-life of 1–3 minutes in plasma. The synthetic analog program that produced octreotide and lanreotide resolved this by substituting D-amino acids and cyclizing the pharmacophore β-turn (Phe-Trp-Lys-Thr), dramatically extending half-life while preserving and sculpting receptor subtype selectivity.

A comprehensive 2025 review of the SSTR family frames the receptors as central inhibitory signaling hubs across endocrine tissues and the molecular target of SSA-class drugs (Endocr Rev, 2025).

---

Molecular Identity and Structural Pharmacology

Lanreotide is a synthetic cyclic octapeptide built on the somatostatin pharmacophore constrained by:

• •A disulfide bridge between Cys residues
• •D-amino acid substitutions (D-Trp, D-Leu, D-Trp²) for protease resistance
• •A β-naphthalamide C-terminal modification for enhanced receptor affinity

Its IUPAC molecular formula is C₅₄H₆₉N₁₁O₁₀S₂ (MW ~1096 Da). In the Autogel/Depot formulation, lanreotide acetate at high concentration self-assembles into nanotubes within an aqueous depot — a unique physical-chemical property that drives its extended-release pharmacokinetics without polymers or additives.

Cryo-EM structural studies of lanreotide and pasireotide binding modes at somatostatin receptors have provided residue-level insight into how the cyclic scaffold docks into the SSTR binding pocket and the molecular basis of SSTR2 subtype preference (Acta Pharm Sin B, 2025). Complementary work mapping SSTR1/SSTR3 selective recognition defines the structural framework against which SSTR2-preferring analogs are interpreted (Proc Natl Acad Sci USA, 2024).

---

Receptor Pharmacology: SSTR2/SSTR5 Profile

Lanreotide's defining pharmacological signature is high-affinity binding at SSTR2 with secondary activity at SSTR5 and minimal engagement of SSTR1, SSTR3, and SSTR4:

This profile distinguishes lanreotide from pasireotide (SSTR1/2/3/5, SSTR5-preferring) and aligns it closely with octreotide (also SSTR2-preferring). The SSTR2-dominant binding drives both its key research utilities:

1. Anti-secretory effects — SSTR2-mediated Gi/o coupling → adenylyl cyclase inhibition → ↓cAMP → suppressed pituitary GH secretion and pancreatic hormones

2. Anti-proliferative effects — SSTR2 activates phosphotyrosine phosphatases (PTP-η, SHP-1/2), inhibits MAPK/PI3K/Akt survival signaling, and induces apoptosis in neuroendocrine tumor cell lines

Molecular pharmacodynamic studies of lanreotide in neuroendocrine research models have characterized its downstream signaling and immune-modulatory effects in NET cell systems (Cancers (Basel), 2024).

---

Formulation: The Aqueous Nanotube Depot

The distinguishing pharmaceutical feature of lanreotide vs. octreotide is the Autogel/Depot formulation architecture:

Lanreotide Somatuline Depot (Autogel)

• •Formulation: Aqueous supersaturated solution of lanreotide acetate self-assembling into nanotubes upon injection into deep subcutaneous tissue
• •No polymers, additives, or reconstitution required — supplied as a ready-to-use prefilled syringe
• •Injection depth: Deep subcutaneous (2–3 cm needle, unlike traditional SC)
• •Injection frequency: Every 28 days (range: 28–56 days)
• •Available doses: 60 mg, 90 mg, 120 mg

Octreotide LAR (for comparison)

• •Formulation: Lyophilized microsphere suspension (PLGA polymer) requiring reconstitution immediately before injection
• •Injection frequency: Every 28 days (LAR formulation) or 3× daily (immediate-release)
• •Reconstitution: Required — complex preparation step

The lanreotide Autogel pharmacokinetics from a Phase I single-dose study in healthy volunteers documented the nanotube depot mechanism producing prolonged-release profiles: mean apparent half-life ~21–23 days, with Cmax achieved within 24–48 hours (Eur J Endocrinol, 2004).

---

Pharmacokinetics

At steady state (multiple 28-day dosing cycles), Somatuline Depot demonstrates linear pharmacokinetics across the 60–120 mg dose range:

Peak-to-trough fluctuation is low (81–108%), enabling sustained receptor occupancy between monthly injections. Bioavailability after deep SC administration is ~70–78% across dose levels. Elimination is primarily biliary (<5% renal excretion unchanged).

---

Research Applications

1. Acromegaly Research Models

Acromegaly is caused by chronic GH hypersecretion (usually from a pituitary somatotroph adenoma), driving excess hepatic IGF-1 synthesis. Lanreotide is the prototypical SSTR2 agonist studied in GH-secreting adenoma models because:

• •SSTR2 and SSTR5 are the dominant subtypes expressed in somatotroph adenomas
• •SSTR2 activation suppresses GH secretion via Gi/o → ↓cAMP pathways
• •Secondary tumor shrinkage (cytostatic, not cytotoxic) has been documented in clinical trials and preclinical somatotroph cell models

Biochemical efficacy data from three multicenter trials demonstrated IGF-1 normalization in 39–52% of treatment-naive acromegaly patients on lanreotide Autogel 60–120 mg/4 weeks (Endocrine, 2018). The GALANT trial (2024) specifically investigated lanreotide for non-functioning pituitary macroadenoma (NFPMA) using 68Ga-DOTATATE PET-positive patient selection to enrich for SSTR-expressing tumors (Lancet Diabetes Endocrinol, 2024).

Research on high-dose and high-frequency lanreotide Autogel regimens in acromegaly resistant to standard dosing explored dose escalation to 120 mg every 3 or 2 weeks, providing a framework for receptor saturation kinetics studies (J Clin Endocrinol Metab, 2017).

2. Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Research

The landmark CLARINET trial (Caplin et al., NEJM 2014; Caplin et al., NEJM 2014 — PMID unverified) established lanreotide's anti-tumor efficacy in GEP-NETs:

• •Design: Phase III, multicenter, randomized, double-blind, placebo-controlled, 96-week trial (204 patients, 48 centers, 14 countries)
• •Population: Well/moderately differentiated GEP-NETs (Grade 1/2; Ki-67 <10%), pancreatic, midgut, hindgut, or unknown primary
• •Intervention: Lanreotide Autogel 120 mg every 28 days vs. placebo
• •Primary endpoint: Progression-free survival (PFS) by central radiology review
• •Results: Lanreotide reduced risk of progression or death by 53% (HR = 0.47; 95% CI 0.30–0.73; P<0.001); median PFS not reached in lanreotide arm vs. 18.0 months placebo; 65.1% of lanreotide patients progression-free at 96 weeks vs. 33.0% placebo

The CLARINET Open-Label Extension (OLE) documented sustained anti-tumor effects and long-term safety with continued lanreotide therapy, including in patients who crossed over from placebo after disease progression (Endocrine, 2021).

A novel tumor growth rate analysis of CLARINET data using radiological modeling to estimate tumor doubling time demonstrated that lanreotide exerts cytostatic effects on NET biology across all tumor burden subgroups, with implications for understanding SSA mechanism in preclinical tumor growth models (Oncologist, 2021).

A systematic review of the antiproliferative role of lanreotide across NET subtypes confirmed consistent tumor stabilization across gastric, intestinal, and pancreatic primary tumors, with anti-proliferative signaling mediated via SSTR2-driven apoptotic pathways (Pancreas, 2017).

3. SSTR2-Targeting Conjugate Chemistry

High-affinity SSTR2 binding makes lanreotide a frequently used targeting scaffold in:

• •Radiolabeled peptide-receptor radionuclide therapy (PRRT) probe design — conjugation of DOTA-chelated radiometals (Lu-177, Y-90, Ga-68) for NET theranostics
• •Drug-antibody conjugate / peptide-drug conjugate research — SSTR2-targeting modifications for experimental conjugate chemistry (Acta Pharmacol Sin, 2025)
• •Fluorescent probe labeling for receptor trafficking and internalization studies in SSTR2-expressing cell lines

4. Comparative Somatostatin Analog Biology

A recurring experimental design is head-to-head comparison of the three canonical SSAs:

Comparative safety-pharmacology surveys of the SSA class map where lanreotide sits among related research reagents across metabolic, immune, and tumor biology contexts (Eur J Pharmacol, 2025; Neuroendocrinology, 2025).

---

Dosing Parameters in Published Research Literature

For researchers contextualizing in vivo data or reviewing clinical pharmacology:

• •Acromegaly (standard): Lanreotide Autogel 90 mg deep SC every 28 days; dose titrated to 60 mg (controlled) or 120 mg (inadequate control) based on GH/IGF-1 response
• •GEP-NETs (CLARINET): Lanreotide Autogel 120 mg deep SC every 28 days
• •Dose escalation (acromegaly refractory): 120 mg every 14–21 days explored in clinical trials (JCEM, 2017)
• •Treatment-naive biochemical control (acromegaly): Three multicenter trials: IGF-1 normalization in 39–52% at 6 months (Endocrine, 2018)
• •Preclinical in vitro: Research-grade lanreotide acetate typically used at 10⁻⁸–10⁻⁶ M for receptor pharmacology assays in SSTR2-expressing cell lines (BON-1, QGP-1, GH3, AtT-20)

---

Supplier Availability and Research-Grade Procurement

Lanreotide is available as research-grade peptide from academic peptide synthesis suppliers and specialty research chemical vendors. Key considerations for researchers:

• •Formulation difference: Research-grade lyophilized lanreotide acetate is distinct from the clinical Autogel/Depot formulation; the nanotube self-assembly requires the specific high-concentration aqueous environment of the commercial product
• •Purity requirements: Confirm cyclic disulfide structure, sequence identity (HPLC, LC-MS), and sterility for cell-based assays; see the Peptides.SO peptide purity testing guide and certificate of analysis guide
• •Reconstitution: Dissolve in aqueous buffer at near-physiological pH; consult the peptide reconstitution guide — cyclic peptides can be challenging due to reduced solubility
• •Comparator recommendation: Run octreotide and/or pasireotide in parallel to deconvolve SSTR2-specific from broader subtype effects
• •Supplier comparison tools: See the Peptides.SO supplier comparison page and supplier evaluation guide

---

Handling and Assay Design Considerations

• •Receptor controls: Because lanreotide engages both SSTR2 and SSTR5, include SSTR2-selective agents (BIM-23197, L-779,976) and SSTR5-selective agents as controls to isolate subtype contributions
• •cAMP assays: HTRF or BRET-based cAMP assays in SSTR2-expressing HEK293 or CHO cells are the reference readout for lanreotide receptor activation
• •Anti-proliferative assays: GH3 (somatotroph), BON-1 (panNET), QGP-1 (panNET), or CM2 (carcinoid) cell lines are commonly used to assess lanreotide-induced growth arrest; measure Ki-67, EdU incorporation, or Annexin V-FITC
• •Internalization studies: SSTR2 undergoes rapid internalization upon agonist binding; lanreotide-induced SSTR2 internalization is slower than somatostatin but faster than octreotide in some cell systems — a useful experimental variable

---

Related Articles on Peptides.SO

• •Somatostatin Receptor Biology Guide — SSTR1–SSTR5 family, signaling mechanisms, and research contexts
• •Octreotide (Sandostatin) Research Profile — the closest SSTR2-preferring matched comparator with FDA approval for acromegaly and carcinoid
• •Pasireotide (SOM230) Research Profile — multi-receptor (SSTR1/2/3/5) comparator for broad subtype coverage
• •Cortistatin (CST-14) Research Profile — somatostatin-related neuropeptide engaging SSTR subtypes in CNS and immune contexts

---

Frequently Asked Research Questions

Is lanreotide FDA-approved?

Yes. Lanreotide (Somatuline Depot) has two FDA approvals: acromegaly (2007) and unresectable, well/moderately differentiated, locally advanced or metastatic GEP-NETs (2014).

What is the CLARINET trial?

CLARINET was a landmark Phase III randomized, double-blind, placebo-controlled trial (NEJM 2014; Caplin et al. — PMID unverified) demonstrating that lanreotide 120 mg every 28 days reduced risk of disease progression or death by 53% (HR 0.47) in GEP-NET patients over 96 weeks — establishing the evidence base for its NET indication.

How does lanreotide's formulation differ from octreotide?

Lanreotide Autogel/Depot forms a self-assembling nanotube depot upon deep subcutaneous injection (no polymers, no reconstitution). Octreotide LAR uses PLGA microspheres requiring reconstitution immediately before injection. Both achieve ~28-day dosing intervals but through distinct formulation mechanisms.

What receptor does lanreotide preferentially bind?

SSTR2 (high affinity) with secondary SSTR5 activity. Structural cryo-EM studies have defined the molecular basis of this subtype preference (Acta Pharm Sin B, 2025).

Can lanreotide shrink pituitary tumors?

In GH-secreting somatotroph adenomas, primary lanreotide therapy induces measurable tumor volume reduction in approximately 30–50% of patients in clinical series — distinct from its hormonal suppression effect. SSTR2 density on the tumor predicts responsiveness. The 2024 GALANT trial explored this in non-functioning macroadenomas with 68Ga-DOTATATE PET selection (Lancet Diabetes Endocrinol, 2024).

What cell lines are used to study lanreotide?

Common SSTR2-expressing research lines: BON-1, QGP-1 (pancreatic NET); GH3 (rat somatotroph); CM2 (carcinoid). Stable SSTR2-transfected HEK293 or CHO cells are used for receptor pharmacology.

---

Summary

Lanreotide (Somatuline Depot/Autogel) is a long-acting cyclic octapeptide somatostatin analog with high SSTR2 affinity (secondary SSTR5) that achieves monthly dosing through a unique self-assembling aqueous nanotube depot formulation. Its two FDA indications (acromegaly 2007; GEP-NETs 2014) anchor a rich research literature in GH suppression, IGF-1 axis biology, anti-proliferative SSTR2 signaling, and NET tumor growth models. The landmark CLARINET trial provided Class I evidence for its anti-tumor role in GEP-NETs (HR 0.47, PFS benefit — PMID unverified). As an SSTR2-preferring analog, it serves as a key matched comparator to octreotide (identical subtype profile, different formulation) and pasireotide (broader multi-receptor SSTR1/2/3/5 coverage) in translational receptor pharmacology research.

This profile is for Research Use Only. Lanreotide is a prescription drug regulated by the FDA. All research uses require institutional compliance with applicable regulations.

> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.